Dr Reddy’s Cheminor merger: A pharma wedding finalised - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Jun 1, 2000 - Dr Reddy’s Cheminor merger: A pharma wedding finalised

Dr Reddy’s Cheminor merger: A pharma wedding finalised

Jun 1, 2000

Dr Reddy’s Laboratories (DRL) is to merge its sister concern Cheminor Drugs (Cheminor) with the merger ratio set at 9 shares of DRL for every 25 shares of Cheminor. The merger will make Dr. Reddy’s the third largest pharmaceutical player in India, with a post- integration turnover of above Rs. 8 billion in FY 2000. The management aims at a turnover of over Rs 10 bn in FY 2001 which it should it able to achieve if the growth in its main brands viz. Omez (anti–ulcer), Nise (anti–pain), Stamlo (cardivascular) and Ciprolet (anti–infective) in FY2000 are any indication. These brands contributed over 40% of the company’s turnover and will continue to be a major driver for the merged company’s topline.

Another driver of the topline would be the generics business in the regulated markets, which was being undertaken via Cheminor. (Cheminor recently entered the global generics markets with the export of Ranitidine-75Mg and Flouxetine to North America.)

The third driver of the integrated company’s turnover would be the revenues from any Novel Drug Discovery (NDDS). At present, DRL itself is working on three new molecules. One is an anti–cancer compound, another was a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future. Besides, the company is also working on a new class of diabetes products called PPAR, expected to have considerable potential.

The main promoter of the group companies, Dr. Reddy’s Holdings (DRH), currently holds 25.40% in DRL and 35.34 % in Cheminor. The holding of DRH in the merged entity will be 27.59%. In their individual capacities, Dr. Anji Reddy and his immediate family members hold 1.76% in DRL and 13.42% in CDL. In the merged entity their combined holding will be 3.86%.

The merger ratio too seems to be slightly weighted in favour of the Cheminor considering the fact that its turnover was Rs 2154 m in FY 2000 i.e. around 36% of the DRL’s turnover. (DRL’s turnover inclusive of American Remedies’ numbers amounted to Rs 5870 m in FY2000.) Moreover growth in the domestic bulk actives market has actually been negative. However weightage seems to have been given to the fact that 67% of Cheminor’s turnover is accounted for by exports and the company has already filed six abbreviated new drug applications (ANDAs) in the US, four in the European Union apart from another six, which are in the pipeline.


Equitymaster requests your view! Post a comment on "Dr Reddy’s Cheminor merger: A pharma wedding finalised". Click here!

  

More Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 18, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS